Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

BACKGROUND: This Phase 1 study assessed the safety and efficacy of the Porcupine inhibitor, WNT974, in patients with advanced solid tumours. METHODS: Patients (n = 94) received oral WNT974 at doses of 5–30 mg once-daily, plus additional dosing schedules. RESULTS: The maximum tolerated dose was not e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Rodon, Jordi, Argilés, Guillem, Connolly, Roisin M., Vaishampayan, Ulka, de Jonge, Maja, Garralda, Elena, Giannakis, Marios, Smith, David C., Dobson, Jason R., McLaughlin, Margaret E., Seroutou, Abdelkader, Ji, Yan, Morawiak, Jennifer, Moody, Susan E., Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8257624/
https://ncbi.nlm.nih.gov/pubmed/33941878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01389-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares